UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

NCT02610543 | Terminated Phase 2 DMC

• 2 other identifiers: SS00042014-004523-51
• Study Type: interventional
• Target: 27
• Locations: 5 countries
• Sites: 14

Brief Summary

This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS). The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.

Conditions

Primary Sjögren's Syndrome

Keywords

Primary Sjögren's Syndrome

Outcome Measures

Primary Outcomes (1)

• Change from Baseline to Week 12 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)

  The ESSDAI is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity

  Week 12

Secondary Outcomes (12)

• Change from Baseline to Week 4 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)

  Week 4

• Change from Baseline to Week 8 in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)

  Week 8

• Change from Baseline to Week 4 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)

  Week 4

• Change from Baseline to Week 8 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)

  Week 8

• Change from Baseline to Week 12 in the EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)

  Week 12

Study Arms (2)

UCB5857

EXPERIMENTAL

UCB5857 once daily for 12 weeks

Drug: UCB5857

Placebo

PLACEBO COMPARATOR

Placebo once daily for 12 weeks

Drug: Placebo

Interventions

UCB5857 DRUG

Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral

UCB5857

Placebo DRUG

Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must be between 18 years and 75 years of age
• Women of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 3 months after their final dose of study drug. Women not agreeing to use birth control must be of non-childbearing potential defined as; permanently sterile, congenitally sterile or postmenopausal for at least 2 years prior to Screening (Visit 1). Women of childbearing potential are required to have a serum pregnancy test taken at Screening (Visit 1), which is confirmed to be negative by urine testing prior to the first dose of study drug at Week 1 (Visit 2) Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active during the study and for 3 months after the last dose of study drug In addition female partner of childbearing potential of male subject must be willing to use a highly effective method of contraception for duration of study and for 3 months after last dose of study drug
• Subject must meet the 2002 AECG (American-European Consensus Group) criteria for Primary Sjӧgren's Syndrome
• Subject must have a serum test positive for anti-SSA/Ro (Ro-52 or Ro-60) and/or anti SSB/La autoantibodies

You may not qualify if:

• Subject has a diagnosis of any other autoimmune disease, ie, secondary Sjögren's syndrome (eg, rheumatoid arthritis, systemic lupus erythematosus
• Subject has a diagnosis of any other sicca syndrome (eg, history of head and neck radiation treatment, sarcoidosis chronic graft-versus-host disease)
• Subject has significant fibromyalgia syndrome as defined by the American College of Rheumatology 2010 classification criteria
• Subject has significant depression as defined by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders
• Subject has oral candidiasis
• Subject is female and is breast-feeding, pregnant, or plans to become pregnant or to start breastfeeding during the study or within 3 months after the final dose of the investigational medicinal product (IMP)
• Subject has evidence of an immunosuppressive state, including human immunodeficiency virus (HIV) infection, hypogammaglobulinemias, T-cell deficiencies, or human T-cell leukemia virus type 1 (HTLV-1)
• o Positive testing for HIV-1/2 at Screening (Visit 1)
• Subject has a history of chronic infections, including but not limited to concurrent acute or chronic viral hepatitis B (HBV) or hepatitis C (HCV)
• Positive testing for HBV at Screening (Visit 1)
• Positive testing for HCV at Screening (Visit 1)
• A subject with a history of a recent serious or life-threatening infection or any current signs or symptoms that may indicate a significant infection at Screening (Visit 1) to randomization, as per the Investigator's clinical judgment is also excluded Subject must have completed any prior anti-infective therapy prior to the first dose of study drug with the exception of anti-infectives taken specifically for the treatment of acne, rosacea, onychomycosis, or vaginal yeast infections; for the prophylaxis of urinary tract infections; or prophylaxis for pre-surgical or pre-procedural reasons (including dental procedures). Note: minocycline may not be used for these purposes
• Subject is at a particularly high risk of significant infection due to their lifestyle and/or occupation
• Subject has received intranasal influenza vaccine within the 8 weeks prior to Screening (Visit 1)
• Subject has significant hematologic abnormalities of hemoglobin \<10.0 g/dL, or white blood cell (WBC) \<2000 /mm\^3, or absolute neutrophil count \<1000 /mm\^3, or platelets \<100,000 /mm\^3 at Screening (Visit 1)

Sponsors & Collaborators

• UCB Celltech: lead
• PRA Health Sciences: collaborator

Study Sites (14)

Ss0004 34

Brest, France

Location

Ss0004 30

Le Kremlin-Bicêtre, France

Location

Ss0004 35

Strasbourg, France

Location

Ss0004 20

L’Aquila, Italy

Location

Ss0004 21

Palermo, Italy

Location

Ss0004 22

Udine, Italy

Location

Ss0004 42

Córdoba, Spain

Location

Ss0004 40

Villajoyosa, Spain

Location

Ss0004 50

Stockholm, Sweden

Location

Ss0004 01

Birmingham, United Kingdom

Location

Ss0004 05

Essex, United Kingdom

Location

Ss0004 04

Leeds, United Kingdom

Location

Ss0004 03

Newcastle upon Tyne, United Kingdom

Location

Ss0004 02

Swindon, United Kingdom

Location

Related Publications (1)

• Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnstrom M, Mariette X, Ng WF, Rosas J, Sanchez Burson J, Triolo G, Barone F, Bowman SJ. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren's syndrome. Rheumatology (Oxford). 2021 Mar 2;60(3):1364-1375. doi: 10.1093/rheumatology/keaa410.

  PMID: 32949140 RESULT

Study Officials

• UCB Cares

  +18445992273 (UCB)

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2015
• First Posted: November 20, 2015
• Study Start: October 1, 2015
• Primary Completion: September 7, 2017
• Study Completion: December 5, 2017
• Last Updated: December 1, 2020

Record last verified: 2020-11

Locations

GB (5); SE (1); FR (3); ES (2); IT (3)